9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023.
By Nuha A. ElSayed, G. Aleppo, V. Aroda, Raveendhara R. Bannuru, F. Brown, Dennis Bruemmer, B. Collins, M. Hilliard, Diana M. Isaacs, Eric L. Johnson and 10 more. Diabetes Care, 2022
659 citations recorded by the source corpus.
The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Subfields: Endocrinology, Diabetes and Metabolism, Genetics
View Paper: https://www.semanticscholar.org/paper/f75bf88f7fa4c4c0cf940dad739ba96bb6d15d64
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
In Genetics
Citations in the corpus
- A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association (2023, background): “Co-utilization of SGLT2 inhibitors and GLP-1RA is recommended to decrease risk in high-risk patients, 145 but the approach to delineating this subset of patients is unclear, and interventional trials demonstrating the cardiovascular benefits of combined SGLT2 inhibitors and GLP-1RAs in those at…”